Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Alzheimer's Disease

Alzheimer's Disease

Part of Dementia

Subtypes of Alzheimer's Disease

Autosomal Dominant Alzheimer's Disease 3 Late-onset Alzheimer's disease 1 Mild dementia due to Alzheimer's disease 1

127 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Alzheimer's Disease

440 trials tracked for Alzheimer's Disease: 98 in phase 3 or 4 and 27 with published results. The most-cited published study has 569 citations.

440Trials tracked
98Phase 3 & 4
0Recruiting
27With published results
Phase distribution
Phase 4 34 Phase 3 64 Phase 2 149 Phase 1 58 Other / NA 135
  1. Phase 3 A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease Completed · 569 cited
  2. Phase 3 18F-AV-1451 Autopsy Study Completed · 449 cited
  3. Phase 3 The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF) Completed · 370 cited
  4. Phase 3 Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease Completed · 352 cited
  5. Phase 3 Depression in Alzheimer's Disease-2 Completed · 247 cited
  6. Phase 3 A Study of Gantenerumab in Participants With Mild Alzheimer Disease Completed · 213 cited
Show 44 more trials
  1. Phase 3 Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Participants With Alzheimer's Disease (MK-4305-061) Completed · 186 cited
  2. Phase 3 Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil Completed · 162 cited
  3. Phase 3 Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil Completed · 162 cited
  4. Phase 3 Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor Completed · 162 cited
  5. Phase 3 Apathy in Dementia Methylphenidate Trial 2 Completed · 114 cited
  6. Phase 3 The Healthy Patterns Sleep Study Completed · 71 cited
  7. Phase 3 Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects Completed · 53 cited
  8. Phase 3 Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease Completed · 53 cited
  9. Phase 4 Markers of Alzheimers Disease and Cognitive Outcomes After Perioperative Care Completed · 38 cited
  10. Phase 3 Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Completed · 29 cited
  11. Phase 3 A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4) Completed · 25 cited
  12. Phase 4 Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease Completed · 15 cited
  13. Phase 3 A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Completed · 14 cited
  14. Phase 4 Detecting an Early Response to Donepezil With Measures of Visual Attention Completed · 13 cited
  15. Phase 3 A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease Completed · 13 cited
  16. Phase 3 Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Completed · 11 cited
  17. Phase 4 Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly Completed · 8 cited
  18. Phase 3 ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease Completed · 5 cited
  19. Phase 3 Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease Completed · 4 cited
  20. Phase 3 A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation Completed · 2 cited
  21. Phase 4 Monitoring Anti-Dementia Drugs by Serum Levels Completed
  22. Phase 4 Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease Completed
  23. Phase 4 Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training Completed
  24. Phase 4 Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline Completed
  25. Phase 4 Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia Completed
  26. Phase 4 16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients Completed
  27. Phase 4 Effects of Simvastatin on Biomarkers Completed
  28. Phase 4 Trial of Carvedilol in Alzheimer's Disease Completed
  29. Phase 4 Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's Completed
  30. Phase 4 Neural Correlates In Mild Alzheimer's Disease Completed
  31. Phase 4 A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type. Completed
  32. Phase 4 Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease Completed
  33. Phase 4 Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease Completed
  34. Phase 4 The Feasibility of Florbetapir Quantitation in Europe Completed
  35. Phase 4 Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease Completed
  36. Phase 4 Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease Completed
  37. Phase 4 Cilostazol Augmentation Study in Dementia Completed
  38. Phase 4 Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44 Completed
  39. Phase 4 Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT) Completed
  40. Phase 4 A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA) Completed
  41. Phase 4 Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study Completed
  42. Phase 4 Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease Completed
  43. Phase 4 The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease Completed
  44. Phase 4 A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer's Disease Completed

Showing the 50 most-cited and recently-updated of 440 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Alzheimer's Disease: what the trials found

Donepezil has been evaluated across multiple studies for its impact on cognitive and functional outcomes. Trials showed changes in MMSE scores 16, ADAS-Cog scores [17, 21], and activities of daily living (ADCS-ADL) 16. Additionally, Donepezil was associated with specific changes in the Selective Reminding Test (SRT) 18 and clinical global impression (CGI) scores 19. One study noted a significant increase in the Hippocampus Connectivity Index (HCI) over 12 weeks 21, while another showed no significant correlation between APOE genotype and the incidence of adverse events for Donepezil 16.

Rivastigmine was shown to result in a change from baseline in ADCS-ADL SIV scores 20. In a separate study, Ramipril was associated with a significant decrease in cerebrospinal fluid (CSF) Angiotensin Converting Enzyme (ACE) levels compared to placebo over 4 months 22, though it did not significantly impact CSF Amyloid Beta-42 levels or flow-mediated vasodilation 22.

Propofol and other anesthetic agents were evaluated for their impact on cognitive indices; however, no significant differences were found in the change of CSF markers of Alzheimer's disease between anesthetic groups 15.

Recent results — preliminary, needs further review

  • Lecanemab (2.5 mg/kg) showed changes in ADCOMS scores at 12 months and significant reductions in brain amyloid pathophysiology as measured by PET at 12 and 18 months 3.
  • Belly-focus meditation was associated with a statistically significant change in plasma Amyloid Beta (Aβ) levels 14, though it did not significantly impact the Ab42/40 ratio or pTau-181/Tau ratio 14.
  • Brain training showed no significant changes in plasma Aβ levels, Ab42/40 ratios, or brain perivascular space volume 13.
  • The MEMORI Corps program was associated with a change in Neuropsychiatric Inventory (NPI) scores 10.

For the clinician treating this condition

  • Donepezil is established as an intervention affecting multiple cognitive markers including MMSE, ADAS-Cog, and functional activities of daily living [16, 17, 21].
  • Rivastigmine has been shown to impact activities of daily living scores in patients with severe impairment 20.
  • While some non-pharmacological interventions like belly-focus meditation show significant changes in plasma Amyloid Beta levels, other methods such as brain training did not produce statistically significant changes in similar biomarkers [13, 14].

AI synthesis of 11 cited trials, updated Jun 20, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Sedative-hypnotic use associated with OR 1.29 for incident Alzheimer's Disease
Neurology Meta-analysis
Sedative-hypnotic use associated with OR 1.29 for incident Alzheimer's Disease Meta-analysis links sedative-hypnotic drug use to higher Alzheimer risk
This meta-analysis of observational cohort and nested case-control studies involving 721,354 adults without baseline dementia found that sed…
A large study suggests a link between the use of common sleep medications like benzodiazepines and an increased risk of developing Alzheimer…
Jul 22, 2026
Bibliometric analysis identifies growing research trends and key hubs for short-chain fatty acids in cognitive impairment
Neurology Sys. Review
Bibliometric analysis identifies growing research trends and key hubs for short-chain fatty acids in cognitive impairment Mapping the Growing Research on Gut Health and Memory Loss Diseases
This systematic review provides a bibliometric analysis of 425 WoSCC and 514 Scopus records regarding short-chain fatty acids (SCFAs) and co…
Scientists are tracking how gut-related compounds might help brain health. This review maps out years of research into these important links…
Frontiers Jul 19, 2026
Berberine identified as potential Alzheimer's treatment targeting HMGCR in astrocyte-driven model
Neurology Guideline
Berberine identified as potential Alzheimer's treatment targeting HMGCR in astrocyte-driven model New research identifies a potential target for Alzheimer's disease
This guideline presents a computational analysis identifying an autolysosome-astrocyte-associated diagnostic model for Alzheimer's disease, …
Scientists identified a specific gene as a key driver of Alzheimer's and found that the compound berberine may help target it.
Frontiers Jul 15, 2026
Adaptive immune signatures and T cell infiltration characterize pathology in Alzheimer's, Parkinson's, and Lewy Body dementia
Neurology Sys. Review
Adaptive immune signatures and T cell infiltration characterize pathology in Alzheimer's, Parkinson's, and Lewy Body dementia Adaptive Immune Signatures Linked to Alzheimer's and Parkinson's Disease
This mini review synthesizes evidence regarding adaptive immune remodeling and T cell responses in neurodegenerative dementias. The authors …
New research highlights how specific immune cell activity may play a role in the progression of Alzheimer's, Parkinson's, and Lewy body deme…
Frontiers Jul 9, 2026
Angiogenic factors in biofluids show no significant difference in Alzheimer's disease
Neurology Meta-analysis
Angiogenic factors in biofluids show no significant difference in Alzheimer's disease Comparing blood markers to see if they help identify Alzheimer disease
This systematic review and meta-analysis of 18 studies found a small, nonsignificant overall effect size for angiogenic factors in biofluids…
Researchers looked at several proteins in the blood to see if they could help tell the difference between healthy people and those with Alzh…
Jul 8, 2026
Exercise training promotes adult hippocampal neurogenesis by influencing the neurochemical environment and cell cycle dynamics
Neurology Sys. Review
Exercise training promotes adult hippocampal neurogenesis by influencing the neurochemical environment and cell cycle dynamics Exercise training may help grow new neurons in the brain
This narrative review synthesizes evidence regarding exercise training and its effects on adult hippocampal neurogenesis in conditions such …
Physical exercise can trigger the growth of new neurons and stem cells, potentially offering new paths for treating brain disorders like Alz…
Frontiers Jul 7, 2026
Hormonal birth control and menopausal hormone therapy associated with greater gray matter volume
Radiology & Imaging RCT
Hormonal birth control and menopausal hormone therapy associated with greater gray matter volume Hormonal Birth Control Linked to Greater Brain Volume in Women
This observational study of 459 women found that hormonal birth control (BC) and menopausal hormone therapy (MHT) were associated with incre…
New research suggests that hormonal birth control and menopausal hormone therapy may be linked to larger brain volume and thicker cortex in …
Jul 6, 2026
APOE ε4 status does not significantly impact neurocognitive performance in adults with HIV infection
Infectious Disease Meta-analysis
APOE ε4 status does not significantly impact neurocognitive performance in adults with HIV infection APOE Status Does Not Impact Cognitive Health in HIV Patients
This meta-analysis of 2610 adults with HIV found no significant difference in cognitive performance or diagnosis of neurocognitive impairmen…
A large review of data suggests that the APOE e4 gene does not change cognitive performance or impairment for adults living with HIV.
Jul 3, 2026
EEG microstate duration and occurrence rates differ significantly between Alzheimer's patients and healthy controls
Neurology Meta-analysis
EEG microstate duration and occurrence rates differ significantly between Alzheimer's patients and healthy controls Brain wave patterns show differences in Alzheimer's and memory loss
This meta-analysis of 16 studies evaluated EEG microstate parameters in patients with Alzheimer's disease (AD) and mild cognitive impairment…
New analysis shows specific brain wave patterns change as memory fades, offering a new way to look at how the brain handles information.
Jul 1, 2026
Plasma p-tau217 and Aβ42/40 biomarkers show high AUC for discriminating amyloid PET positivity
Neurology Meta-analysis
Plasma p-tau217 and Aβ42/40 biomarkers show high AUC for discriminating amyloid PET positivity Blood Tests May Help Identify Early Signs of Alzheimer's
This meta-analysis of 9 studies involving 2566 cognitively unimpaired Asian individuals found that plasma p-tau217 (AUC 0.88) and Aβ42/40 (A…
New research shows that specific blood markers can help identify early signs of amyloid buildup in the brain for people without memory loss.
Jul 1, 2026
194 miRNAs exhibit widespread changes in Alzheimer's disease and influence key biological pathways
Neurology Meta-analysis
194 miRNAs exhibit widespread changes in Alzheimer's disease and influence key biological pathways 194 microRNAs show widespread changes in Alzheimer's disease
This meta-analysis of 22 studies identifies 194 miRNAs with widespread changes in Alzheimer's disease. The analysis highlights the involveme…
A meta-analysis of 22 studies found 194 microRNAs with widespread changes in Alzheimer's disease, including novel ones. These miRNAs affect …
Jul 1, 2026
Combined plasma p-tau217 and tau-PET identify high-risk patients with hazard ratios up to 9.98
Neurology RCT
Combined plasma p-tau217 and tau-PET identify high-risk patients with hazard ratios up to 9.98 Blood Tests and Brain Scans Help Predict Alzheimer Disease Progress
This observational study of 330 cognitively unimpaired, Amyloid-beta positive older adults found that the T+ T+ biomarker profile predicted …
Combining blood tests with brain scans can identify which individuals are at the highest risk for rapid cognitive decline in early Alzheimer…
Jun 26, 2026

Questions about Alzheimer's Disease

What is the link between Periodontal Disease and Alzheimer's disease risk?

Periodontal disease is linked to a higher risk of Alzheimer's disease, likely through inflammation and oral bacteria reaching the brain, but a direct cause is not proven.

Full answer →
Is there a genetic link between kidney function and Alzheimer Disease for my family?

Current research finds no overall genetic link between kidney function and Alzheimer disease, though some shared biological pathways may exist.

Full answer →
Does having brain reserve protect me from Alzheimer Disease symptoms if I am inactive?

Research shows that having more brain reserve, such as from higher education, can help maintain cognitive function even when Alzheimer's disease pathology is present, even in people who are physically inactive.

Full answer →
Are there new genetic markers for Alzheimer disease found in veteran populations?

Yes, a meta-analysis of the VA Million Veterans Program identified 17 new genetic loci in European, 4 in African, and 3 in Hispanic veteran populations for Alzheimer's disease.

Full answer →
Do genetic tests find new risk factors for Alzheimer's in veteran populations?

Yes, genetic tests can find new risk factors for Alzheimer's in veteran populations, as shown by a meta-analysis including the VA Million Veterans Program that identified 17 new genetic loci in European ancestry veterans.

Full answer →
What is the new FDA-approved medication for agitation in Alzheimer's disease?

The FDA has approved Auvelity (dextromethorphan/bupropion) for treating agitation in Alzheimer's disease, making it the first medication specifically approved for this indication.

Full answer →
Can exercise programs really improve sleep quality for people with Alzheimer's disease?

Yes, exercise programs can improve subjective sleep quality in people with Alzheimer's disease, based on a meta-analysis of 12 randomized trials showing a significant reduction in PSQI scores.

Full answer →
See all 7 questions about Alzheimer's Disease →

All Alzheimer's Disease Articles